Nemosia has developed the world's first positron emission tomography (PET) tracer that specifically targets the NMDA receptor, enabling precise imaging of neurodegenerative disorders. This technology facilitates early diagnosis and monitoring of conditions such as Alzheimer's and Parkinson's disease, improving patient outcomes through timely intervention.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for neurodegenerative diseases often lack the sensitivity to detect early-stage changes, hindering timely intervention and effective disease management. Existing positron emission tomography (PET) tracers do not specifically target key receptors involved in neurodegeneration, limiting the accuracy of imaging and diagnostic capabilities.
Solution
Nemosia has developed a novel positron emission tomography (PET) tracer that selectively binds to the NMDA receptor, a critical target in neurodegenerative processes. This first-in-class tracer enables high-resolution PET imaging of NMDA receptor density and distribution in the brain, providing a more precise method for early diagnosis and monitoring of diseases like Alzheimer's and Parkinson's. By visualizing changes in NMDA receptor function, Nemosia's technology offers clinicians a powerful tool to differentiate between various neurodegenerative conditions, assess disease severity, and track treatment response. The tracer has demonstrated proof-of-concept in animal studies and is currently undergoing clinical trials to validate its efficacy in humans.
Target Audience
The primary target audience includes neurologists, radiologists, and pharmaceutical companies involved in the development of therapies for neurodegenerative diseases, as well as clinical research centers focused on early disease detection and diagnosis.
Features
- First PET tracer targeting the NMDA receptor for neurodegenerative disease imaging
- High specificity and affinity for the NMDA receptor, enabling precise quantification of receptor density
- Demonstrated successful synthesis and evaluation in non-human primates
- Potential for early detection and differential diagnosis of Alzheimer's, Parkinson's, and other neurodegenerative disorders
- Facilitates monitoring of disease progression and treatment response
- Streamlines clinical trials for novel therapeutics targeting NMDA receptor modulation
- Global patent filed in 2018